medartis group



The Group with the special TOUCH

Peter Hackel, CFO

Zurich, 5 November 2026

ZKB Swiss Equity Seminar

From head to toe








Market segment	CMF	Upper extremities[2]	Lower extremities	Total addressable market
Segment size m CHF TAM / (SAM)[1]	1,800 (500)	2,500 (1,700)	2,800 (1,600)	7,100 (~4,000)
Main competitors	Stryker, Synthes, KLS Martin, Materialise	Stryker, Synthes, Acumed, Skeletal Dynamics, KLS Martin	Zimmer Biomet, Stryker, Synthes, Arthrex, Acumed	

[1] Total addressable market represents the entire revenue opportunity based on our activity field with no operational constraints. Serviceable Addressable Market is the portion which we can directly target, given our geographic reach and product portfolio [2] Soft-tissue and total shoulder prostheses are not incl. in the upper limb TAM. Source. SmartTrak 2025

Business highlights 2026




H1 2026 | Positive US momentum continues with 27% growth





EBITDA | Core profitability increased thanks to OPEX leverage



- Core EBITDA margin increased +0.9 PP at CER
- Investment in growth initiatives while keeping overall cost discipline
- NeoOrtho with positive effect on EBITDA margin

Strategy update



The Medartis Group

medartis group


	medartis	KeriMedical medartis group	NeoOrtho medartis group
Brand			
Ownership Stake		100%	51%
Consolidated		July 2025	May 2025


TOUCH® I the mini hip implant for the hand


Prevalence of osteoarthritis in the different joints

medartis group

Prevalence of Osteoarthritis (55-74y old age group)




CMC 1 arthroplasty market penetration[1]



1 Internal estimation based on internal & external market data

Firmly on track to meet our full-year TOUCH projection



+45% Keri Medical[1] sales growth in Medartis's direct-distribution countries (e.g. Austria, Germany, UK)

+30% Keri Medical[1] sales growth with external distribution partners (incl. French and Belgian markets)


3,000 TOUCH units projected for the US rollout in 2026, raised from initially 1,200

[1] KeriMedical sales include its flagship TOUCH® CMC 1 prosthesis for thumb arthritis as well as KeriFlex®, a silicone implant for MCP and PIP finger joints.


CMC1 will expand the thumb arthritis market

medartis group

French market data[1]




French surgeon practice preferences[1]



Source:
1 2 Prosthesis is the new Gold Standard for rhizarthrosis surgery in France, Harouna Abdoulaye-Diallo, Hand Surg Rehabilitation; 2026 June

New ‘Titan Nail’ launched in August I excellent feedback from American surgeons right from the start



- ‘Titan Nail’ is an intramedullary implant that stabilises the bone from within rather than through a plate-and-screw construct
- Designed to reduce soft-tissue exposure and operating time in suitable indications
- Delivered via a new procedure kit designed to be flexible and asset-light for hospitals to use
- Important addition to the upper limb portfolio and an improved alternative to the NX nail system previously sourced from a 3rd party vendor
- We will gradually phase out the NX nail and transition to our proprietary technology

The new Proximal Humerus targets a top3 indication

medartis group

Major trauma indication

Addressing a top-3 indication in elbow trauma where we are not present today

New PentaLock locking system

For selected indications, complementing the APTUS portfolio

Anatomical plate design


Fits individual bone and soft-tissue conditions, featuring a spiral blade (RHS: gold) for extra stability




Outlook 2026



Accelerating momentum



Our education centers: From 1 to 3 continents



Research and Patent Development
Ability for research projects from design to patent development

Q&A



ONE TEAM

Executive Management Board

As of 1 January 2027

medartis group



CEO
Matthias Schupp





KeriMedical Advisory Board
DOUGAL BENDJABALLAH & BERNARD PRANDI



CEO Assistant – Board Secretary
Antonietta Fasolin



COO
MARIO DELLA CASA



CFO and US a.i.
PETER HACKEL



GM Keri Medical
Julie Mottet



CEO NeoOrtho &
EVP LATAM
Pablo Prado



President EMEA
MAREIKE LOCH



EVP R&D
MARC AMMANN



CHRO
CAROLINE KNOERI

Upcoming corporate events

Date	Event	Destination	Broker	Broadcasting
05 November	Swiss Equities Conference	Zurich	ZKB	
19 November	Healthcare Conference	London	Jefferies	
20 November	Non-deal roadshow	London	UBS	
12 January	Swiss Equities Seminar	Davos	Octavian	
02 March	2026 full-year results publication	Basel		Yes
22 April	Annual General Meeting 2027	Basel		Yes



Investors: investor.relations@medartis.com
Journalists: corporate.communication@medartis.com

Analyst coverage: For independent research opinions

Broker	Analyst	Email	Telephone
Octavian	Sandra Dietschy	sandra.dietschy@octavian.ch	+41 44 518 08 27
Research Partners AG	Eugen Perger	eugen.perger@researchpartners.ch	+41 44 533 40 30
Stifel Nicolaus Europe Ltd.	Edward Hall	ed.hall@stifel.com	+44 7584 240 168
UBS	Tanya Hansalik	tanya.hansalik@ubs.com	+41-44-239-2053
Zürcher Kantonalbank (ZKB)	Daniel Jelovcan / Michelle Büchler	michelle.buechler@zkb.ch	+41 44 292 89 46

Brokers listed alphabetically



Need support / further questions?

investor.relations@medartis.com +41 61 633 37 36

Hochbergerstrasse 60E 4057 Basel/Switzerland M E D A R T I S . C O M